Trastuzumab deruxtecan in HER2-positive metastatic colorectal cancer: less is more?
- PMID: 39116901
- DOI: 10.1016/S1470-2045(24)00397-8
Trastuzumab deruxtecan in HER2-positive metastatic colorectal cancer: less is more?
Conflict of interest statement
We declare no competing interests.
Comment on
-
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial.Lancet Oncol. 2024 Sep;25(9):1147-1162. doi: 10.1016/S1470-2045(24)00380-2. Epub 2024 Aug 5. Lancet Oncol. 2024. PMID: 39116902 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
